Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 16/20 | 0.55 |
| ▸ | GSK3B | P49841 | 10/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31562313 | 0.99 | CDK2 (0.60) | CDK2USP30CCNE1GSK3BCCNA2 | |
| SCHEMBL31562544 | 0.90 | CDK2 (0.57) | CDK2USP30CCNE1GSK3BCCNA2 | |
| SCHEMBL31562523 | 0.88 | CDK2 (0.58) | CDK2USP30CCNE1GSK3B | |
| SCHEMBL31562254 | 0.87 | CDK2 (0.58) | CDK2USP30CCNE1GSK3B | |
| SCHEMBL31562358 | 0.87 | CDK2 (0.69) | CDK2CCNE1GSK3B | |
| SCHEMBL31562847 | 0.87 | CDK2 (0.69) | CDK2CCNE1GSK3B | |
| SCHEMBL31562316 | 0.85 | CDK2 (0.66) | CDK2CCNE1GSK3B | |
| SCHEMBL31562342 | 0.85 | CDK2 (0.66) | CDK2CCNE1GSK3B | |
| SCHEMBL31562644 | 0.85 | CDK2 (0.66) | CDK2CCNE1GSK3B | |
| SCHEMBL31562196 | 0.84 | CDK2 (0.67) | CDK2CCNE1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | CDK2 1/4885USP30 2320/4885CCNE1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.